Abstract
Background: Antithrombotic adjuncts to fibrinolytic drugs for acute myocardial infarction increase the rate and speed of infarct artery recanalization.
Hypothesis: A low—molecular—weight heparin might be preferable to unfractionated heparin for this indication, as it has been shown to be in several other thrombus‐related vascular disorders.
Methods: We performed a pilot study in 20 patients, all receiving aspirin and recombinant tissue plasminogen activator. Randomization was to standard dose intravenous unfractionated heparin or enoxaparin (the first dose given intravenously and followed by a subcutaneous administration). The endpoint was stability of anticoagulant effect.
Results: Enoxaparin produced stable therapeutic anti—Xa levels with minimal effect on activated partial thromboplastin times. Unfractionated heparin produced wide swings of these parameters, often outside desired levels.
Conclusions: Enoxaparin may be a better antithrombotic agent than conventional unfractionated heparin when used in conjunction with fibrinolytics.
Keywords: pilot study, low—molecular—weight heparin, unfractionated heparin, acute myocardial infarction, enoxaparin
Full Text
The Full Text of this article is available as a PDF (329.3 KB).
References
- 1. GISSI investigators: Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1: 397–402 [PubMed] [Google Scholar]
- 2. The ISAM study group : A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465–1471 [DOI] [PubMed] [Google Scholar]
- 3. Kennedy JW, Martin GV, Davis KB, Maynard C, Stadius M, Sheehan FH, Ritchie JL: The Western Washington intravenous streptokinase in acute myocardial infarction randomized trial. Circulation 1988; 77: 345–352 [DOI] [PubMed] [Google Scholar]
- 4. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360 [PubMed] [Google Scholar]
- 5. Verstraete M, Bleifeld W, Brower RW, Charbonnier B, Collen D, de Bono DP, Dunning AJ, Lennane RJ, Lubsen J, Mathey DG, Michel PL, Raynaud PH, Schofer J, Vahanian A, Vanhaecke J, Van de Kley GA, Van de Werf F, von Essen R: Double‐blind randomised trial of intravenous tissue‐type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 2: 965–969 [DOI] [PubMed] [Google Scholar]
- 6. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo‐Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; 2: 525–530 [DOI] [PubMed] [Google Scholar]
- 7. National Heart Foundation of Australia Coronary Thrombolysis Group : Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of acute myocardial infarction. Lancet 1988; 1: 203–208 [PubMed] [Google Scholar]
- 8. AIMS Trial Study Group : Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo‐controlled clinical trial. Lancet 1988; 1: 545–549 [PubMed] [Google Scholar]
- 9. AIMS Trial Study Group : Long‐term effects of intravenous anistre‐plase in acute myocardial infarction: Final report of the AIMS study. Lancet 1990; 335: 427–431 [PubMed] [Google Scholar]
- 10. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitmen BR, Ross AM: A comparison between heparin and low‐dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin‐Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990; 323: 1433–1437 [DOI] [PubMed] [Google Scholar]
- 11. de Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, Lopez Bescos L, Mueller E, Pfisterer M, Van de Werf F, Zijlstra F, Verstraete M: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after al‐teplase thrombolysis: Results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–128 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Tebbe U, Windeler J, Boesl I, Hoffman H, Wojcik J, Ashmawy M, Rudiger Schwarz E, von Loewis P, Rosemeyer P, Hopkins G, Barth H: Thrombolysis with recombinant unglycosylated single‐chain urokinase‐type plasminogen activator (saruplase) in acute myocardial infarction: Influence of heparin on early patency rate (LIMITS study). Liquemin In Myocardial Infarction during Thrombolysis with Saruplase. J Am Coll Cardiol 1995; 26: 365–373 [DOI] [PubMed] [Google Scholar]
- 13. Granger CB, Becker R, Tracy RP, Califf RM, Topol EJ, Pieper KS, Ross AM, Roth S, Lambrew C, Bovill EG: Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: Results from the GUSTO‐I Trial. GUSTO‐I Hemostasis Substudy Group. Global Utilization of Strepotokinase and tPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31: 497–505 [DOI] [PubMed] [Google Scholar]
- 14. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F: A comparison of low‐molecular‐weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non‐Q‐wave Coronary Events Study Group. N Engl J Med 1997; 337: 447–452 [DOI] [PubMed] [Google Scholar]
- 15. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non‐Q‐wave myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI) ***1lB trial. Circulation 1999; 100: 1593–1601 [DOI] [PubMed] [Google Scholar]
- 16. Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, Keren G: Reduction of reinfarction and angina with use of low‐molecular‐weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145–1148 [DOI] [PubMed] [Google Scholar]
- 17. Frostfeldt G, Ahlberg G, Gustafsson G, Helmius G, Lindahl B, Nygren A, Siegbahn A, Swahn E, Venge P, Wallentin L: Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction‐a pilot study: Biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627–633 [DOI] [PubMed] [Google Scholar]
- 18. Kontny F, Dale J, Abildgaard U, Pedersen TR, on behalf on the FRAMI Study Group: Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997; 30: 962–969 [DOI] [PubMed] [Google Scholar]
- 19. Baird S, McBride S, Trouton T, Wilson C: LMWH versus unfractionated heparin following thrombolysis in myocardial infarction. J Am Coll Cardiol 1998; 31 (suppl A): 191 [Google Scholar]